Stay updated with breaking news from Kuldip Dave. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Coave Therapeutics (‘Coave’), a genetic medicine company focused on developing life-changing therapies, is delighted to announce that it is one of six organisations sharing $2.9 million in grants from the ALS Association that support the advancement of novel therapies for the treatment of amyotrophic lateral ...
To explore Oryzon’s clinical candidate ORY-4001 in ALS The ALS Association to provide 500,000 USD funding MADRID, Spain and BOSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, announced today the start of a preclinical collaboration with the ALS Association. The Association has awarded Oryzon a 498,690 USD grant through i
/PRNewswire/ -- ALS Finding a Cure® (ALSFAC) and The ALS Association announced today seven new grants worth a total of $2 million to support the development of...
/PRNewswire/ -- The Association for Frontotemporal Degeneration (AFTD) and The ALS Association are launching a funding opportunity to support collaborative...
/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today...